Login to Your Account



DBV, Stallergenes in $198M Pact on Birch Pollen Allergy Therapy

By Cormac Sheridan
Staff Writer

Friday, October 18, 2013
Shares in DBV Technologies SA gained more than 9 percent Friday on news of a licensing deal on a treatment for birch (Betula verrucosa) pollen allergy with Stallergenes SA, which is worth up to 145 million (US$198 million) in milestone payments, as well as royalties on potential product sales.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription